Kenneth J Clemetson

Title: Innovations of Kenneth J Clemetson

Introduction

Kenneth J Clemetson is a notable inventor based in Bern, Switzerland. He has made significant contributions to the field of biomedical research, particularly in the area of blood coagulation disorders. His work has led to advancements that may improve treatment options for various cardiovascular diseases.

Latest Patents

Kenneth J Clemetson holds 2 patents. His latest patent is titled "Recombinant platelet collagen receptor glycoprotein VI and its pharmaceutical use." This invention focuses on Glycoprotein VI (GPVI), detailing its isolation, purification, and methods for recombinant production. The invention emphasizes the use of GPVI, particularly recombinant GPVI, in treating disorders related to blood coagulation, such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be utilized for establishing screening assays to identify potential inhibitors of the membrane-bound GPVI, which may inhibit the binding of thrombocytes and platelets to collagen. Additionally, changes in GPVI can be monitored to assess platelet age and exposure to thrombotic and cardiovascular diseases.

Career Highlights

Kenneth J Clemetson is associated with Aventis Pharma Deutschland GmbH, where he continues to contribute to innovative research and development in pharmaceuticals. His expertise in the field has positioned him as a key figure in advancing medical treatments related to blood disorders.

Conclusion

Kenneth J Clemetson's work exemplifies the impact of innovation in the medical field, particularly in addressing critical health issues related to blood coagulation. His patents and ongoing research hold promise for future advancements in treatment options for cardiovascular diseases.